
Prostate MRI Fusion Biopsy Case Presentations

Greg D Bianchi, MD, Department of Urology
Lauren MB Burke, MD, Department of Radiology
Eric M Wallen, MD, Department of Urology

Case 1

- 69-year-old healthy man with low risk, low volume Gleason 3+3, T1c Pca seen on 3 biopsies -- 2010, 2011 and 2013
- Patient has been on active surveillance. Agree?
- Last surveillance biopsy 2013:
 - a. Gleason 3+3(Grade group 1) in 1/6 cores of "right prostate," <1 mm, est. <5% of total core length
 - b. Gleason 3+3(Grade group 1) in 2/8 cores of "left prostate," <1 mm and 5 mm est. 10% of total core length

Year	PSA
2010	4.5
2011	4.7
2012	3.9
2014	5.3
2016	6.2







Case 1

- Multi para metric MRI results:
 - •0.8×0.5×0.9 cm lesion left peripheral zone posterolaterally at midportion of gland (PIRADS 4)
 - •0.7x 5.3 x 0.6 cm lesion right peripheral zone posterolaterally at the midportion of the gland (PIRADS 4)


Case 1: Lesion #1 (left peripheral zone posterolaterally)
Fusion Biopsy Images







Case 1: Lesion #2 (right peripheral zone posterolaterally)

Fusion Biopsy Images





Case 1: Fusion Biopsy Summary (schematic biopsies done as well)



Case 1: MRI Fusion and Schematic Biopsy Pathology

A: Prostate, target lesion #1, core biopsy

- Prostate adenocarcinoma, Gleason combined score 9(4+5); involving 5 of 6 core fragments; 1 mm, 2 mm, 4 mm, 9 mm and 9 mm in linear extent; approximately 90% of total cores length.
- Perineural invasion present
- Prognostic Group Grade V

B: Prostate, target lesion #2, core biopsy

- Prostate adenocarcinoma, Gleason combined score 7(4+3); involving 1 of 5 core fragments; 2 mm in linear extent; approximately <5% of total cores length.
- Prognostic Group Grade III

C: Prostate, right base, core biopsy

- Benign prostatic glands and stroma with focal seminal vesicle present

D: Prostate, right mid, core biopsy

- Prostate adenocarcinoma, Gleason combined score 7(4+3); involving 1 of 2 cores; 2 mm in linear extent; approximately 8% of total cores length.
- Prognostic Group Grade III

E: Prostate, right apex, core biopsy

- Benign prostatic glands and stroma with chronic inflammation and atrophy

F: Prostate, left base, core biopsy

- Prostate adenocarcinoma, Gleason combined score 7(4+3); involving 1 of 2 cores; 6 mm in linear extent; approximately 25% of total cores length.
- Prognostic Group Grade III

G: Prostate, left mid, core biopsy

- Prostate adenocarcinoma, Gleason combined score 7(3+4); involving 2 of 6 core fragments; 3 mm and 5 mm in linear extent; approximately 40% of total cores length.
- Prognostic Group Grade II

H: Prostate, left apex, core biopsy


- Benign prostatic glands and stroma

Case 2

- 70-year-old gentleman with low-grade low volume prostate cancer currently on active surveillance. Previous prostate biopsy (outside April 2014) demonstrated Gleason 3+3 in 3 of 5 cores "left prostate"
- PSA 01/21/2016: 11.2 ng/mL
- Recommendation: MP MRI to potentially evaluate targets prior to AS biopsy




Case 2: MP MRI




Case 2: MP MRI Sept 2015

- 2 lesions identified
 - 1.9 x 0.8 x 1.5 cm lesion within the transition zone on the left anterior base and left anterior mid prostate (PIRADS 5)
 - 1.3 x 0.6 x 1.0 cm left mid anterior stroma (PIRADS 3)



Fusion Biopsy images (lesion 1)



Fusion and Schematic Biopsy Pathology

```
Diagnosis:
A: Prostate, right apex, needle biopsy
- Benign prostatic glands and stroma, no tumor seen
B: Prostate, right mid, needle biopsy
- Benign prostatic glands and stroma, no tumor seen
C: Prostate, right base, needle biopsy
- Benign prostatic glands and stroma, no tumor seen
D: Prostate, left apex, needle biopsy
- Benign prostatic glands and stroma, no tumor seen
E: Prostate, left mid, needle biopsv
- Prostate adenocarcinoma, Gleason combined score 6 (3+3, grade group 1),
involving 1 of 2 cores, length of carcinoma 1.5 mm, 10% of tissue involved with
carcinoma
F: Prostate, left base, needle biopsy
- Prostate adenocarcinoma, Gleason combined score 6 (3+3), grade group 1),
involving 1 of 3 cores, length of carcinoma 3 mm, 20% of tissue involved with
carcinoma
G: Prostate, anterior mid base, Lesion #1, core biopsy
- Prostate adenocarcinoma, Gleason combined score 7 (3+4, grade group 2),
involving 3 of 3 cores, lengths of carcinoma 5 mm, 2 mm and 2 mm, 40% of tissue
involved with carcinoma
H: Prostate, anterior left apex, Lesion #2, core biopsy
- Prostate adenocarcinoma, Gleason combined score 6 (3+3, grade group 1),
involving 3 of 4 cores, lengths of carcinoma 4 mm, 2 mm and 1 mm, 20% of tissue
involved with carcinoma
```

Patient management


- Informed of higher risk prostate cancer, Gleason 3+4, (Grade group 2)
- •Attended MDC clinic, met with urology and radiation oncology
- •Elected Robotic-assisted laparoscopic radical prostatectomy with bilateral nerve sparing

```
FSA: Bladder neck, right, biopsy
- Stroma only, no invasive carcinoma identified
FSB: Bladder neck, left, biopsy
- Stroma and focal crush artifact, negative for carcinoma by IHC
FSC: Prostate, apical, anterior, biopsy
- Stroma and focal crush artifact, negative for carcinoma by IHC
D: Lymph nodes, bilateral, regional node dissection
- No metastatic carcinoma identified (0/7)
E: Prostate, radical prostatectomy
Tumor histologic type:
                            adenocarcinoma
Tumor grade (Gleason system): 3+4 (grade group 2)
Approximate percentage of prostate involved: 10%
Extent of invasion:
     Location of tumor involvement in prostate: bilateral, apex to mid,
posterior and anterior
     Confinement within the prostatic capsule:
                                                   confined
     Lymphovascular invasion:
                                 not involved
     Seminal vesicle invasion:
                                  not involved
Histologic assessment of surgical margins:
                                              not involved
Other significant findings: nodular hyperplasia
                  separately submitted, see specimen D above, 0/7 total
Lymph nodes:
AJCC Stage (prostate primary): pT2c pN0 pMx
```

Case 3: Elevated, Rising PSA in the context of prior negative biopsy


- 68 yo man with LUTS and elevated PSA
 - biopsy in 2011: 35 g volume, negative for malignancy
- PSA increasing from 6.25 in 2015 to 7.8 2016, repeat was 9.36
- Multi para metric MRI recommended prior to biopsy





MP MRI: Large anterior target

- 2.5 x 1.6 x 2.1 cm lesion anterior transition zone extending from base to apex (PIRADS 5)
- Fusion biopsy



Pathology

Diagnosis: A: Prostate, right apex, needle biopsy - Benign prostatic glands and stroma - No evidence of malignancy B: Prostate, right mid, needle biopsy - Benign prostatic glands and stroma - No evidence of malignancy C: Prostate, right base, needle biopsy - Benign glands and stroma - No evidence of malignancy D: Prostate, left apex, needle biopsy - Adenocarcinoma Gleason grade 3+3=6 (Grade group 1) - Tumor involves 2 of 3 tissue cores - Tumor measures a total of 6 mm of 34 mm combined score length (18%) E: Prostate, left mid, needle biopsy - Atypical small acinar proliferation; inconclusive for malignancy F: Prostate, left base, needle biopsy - Benign prostatic glands and stroma - No evidence of malignancy G: Prostate, target #1, anterior transitional zone, core biopsy

- Adenocarcinoma, Gleason's grade 3+4=7 (Grade group 2)
- Tumor is present in 2 of 4 tissue cores
- Tumor measures aggregate 15 mm of 52 mm combined score length (29%)

Treatment

- Patient elected robotic-assisted laparoscopic radical prostatectomy, non-nerve sparing completed 06/16/2016.
- Surgical Pathology is pending

Case 4: 56 yr old man on active surveillance

- low risk Pca diagnosed 11/04/2014, PSA 3.8 ng/mL
- PBx (11/3/14):

```
TRUS volume = 44 g
```

LEFT medial base = 3+3, 8%

LEFT lateral apex = 3+3, 4%

RIGHT medial mid = 3+3, 50%

RIGHT lateral mid = 3+3, 38%

RIGHT lateral apex = 3+3, 6%


PSA history

5/28/13 = 3.2

6/5/12 = 2.34

5/16/11 = 1.77

- Is there a biomarker test to offer?
- PSA late 2015 = 5.3
- MP MRI rec prior to biopsy





Case 4: Prostate Fusion and Schematic Biopsy Pathology

Final Diagnosis

- A: Prostate, right apex, needle biopsy
- Benign prostatic glands and stroma.
- B: Prostate, right mid, needle biopsy
- Benign prostatic glands and stroma.
- Mild chronic prostatitis.
- Focal acute prostatitis.
- C: Prostate, right base, needle biopsy
- Benign prostatic glands and stroma.
- D: Prostate, left apex, needle biopsy
- Benign prostatic glands and stroma.
- E: Prostate, left mid, needle biopsy
- Benign prostatic glands and stroma.
- F: Prostate, left base, needle biopsy
- Benign prostatic glands and stroma.
- G: Prostate, target lesion #1, core needle biopsy
- Prostatic adenocarcinoma, Gleason combined score 7 (3+4), Grade Group 2, involving 4 of 4 cores, approximately 7 mm, 5 mm, 4 mm and 3 mm in linear extent, approximately 54% of total core length.
- High-grade prostatic intraepithelial neoplasia.


Case 4: Disposition

- MDC appt with urology and radiation oncology
- Patient is still deciding between surgery and radiation


Case 5: Elevated PSA and Recurrent Prostatitis

- 63 year-old with a history of multiple bouts of prostatitis and baseline PSA 20 for years, intermittently on abx
- PSA 2013 20; biopsy negative (+ for inflammation)
- PSA 2014 21; biopsy negative (inflammation again seen)
- PSA 2015 32; MP MRI prior to next biopsy





MP MRI result: $1.7 \times 1.2 \times 1.2$ lesion within the anterior transition zone at the mid and base of the prostate (PIRADS 4)



Fusion and schematic biopsy result

A: Prostate, target lesion #1, biopsy

- Prostate adenocarcinoma, Gleason combined score 7(3+4); involving 5 of 8 cores; 3 mm, 5 mm, 8 mm, 10 mm, and 11 mm in linear extent; approximately 49% of total collength (see comment)
- Prognostic Group Grade II

B: Prostate, right base, biopsy

- Benign prostatic glands and stroma with chronic inflammation and partial atrophy

C: Prostate, right mid, biopsy

- Benign prostatic glands and stroma (see comment)

D: Prostate, right apex, biopsy

- Prostate adenocarcinoma, Gleason combined score 6(3+3); involving 1 of 2 cores; 2 mm in linear extent; approximately 9% of total cores length (see comment)
- Prognostic Group Grade II

E: Prostate, left base, biopsy

- Benign prostatic glands and stroma with partial atrophy (see comment)

F: Prostate, left mid, biopsy

- Benign prostatic glands and stroma with chronic inflammation and partial atrophy (see comment)

G: Prostate, left apex, biopsy

- Benign prostatic glands and stroma with chronic inflammation and partial atrophy (see comment)

Disposition

Considering surgery and radiation currently